Last updated: 2026-09-08 10:22:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Enanta Pharmaceuticals, Inc. (ENTA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $14.13, with a market capitalization of $410.09M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.05 to $17.15. This page covers its latest market performance, valuation, price trends and company information.
$410.09M | |
$14.29 | |
$127.77 | |
$4.09 | |
$14.02 | |
203.56K | |
215.65K | |
-- | |
$17.15 | |
$7.05 | |
-- | |
-- |
Enanta Pharmaceuticals, Inc. (ENTA) is trading at $14.29 in pre-market trading as of 2026-09-04 23:31:00, up 1.92% ($0.27) from the previous close of $14.02
Pre-market trading shows how investors are pricing ENTA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Enanta Pharmaceuticals, Inc. (ENTA) moved from $13.80 to $14.13, representing a gain of 2.36% ($0.33).
The stock traded between $13.12 and $14.34 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 237.79 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 70.1%
ENTA is currently trading at $14.13, placing it 70.1% of the way from its 52-week low of $7.05 to its 52-week high of $17.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 120 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Enanta Pharmaceuticals, Inc. (ENTA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.